Henry C. Rath - Mar 1, 2022 Form 4 Insider Report for Surface Oncology, Inc. (SURF)

Signature
/s/ Jessica Fees, as Attorney-in-Fact
Stock symbol
SURF
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 07:00 PM
Next filing
Aug 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SURF Common Stock Award $0 +38K $0.00 38K Mar 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SURF Stock Option (Right to Buy) Award $0 +108K $0.00 108K Mar 1, 2022 Common Stock 108K $3.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest as follows: 40% on August 1, 2022 and the remaining 60% on August 1, 2023, so long as the reporting person remains an employee or other service provider of the Issuer on such date.
F2 The option vests in equal monthly installments over four years, so that all of the underlying shares shall be vested on February 8, 2026, so long as the reporting person remains an employee or other service provider of the Issuer on such dates.